GW Pharmaceuticals Stocks Soar After Successful Epilepsy Trial
GW Pharmaceuticals stocks have soared yet again after a clinical trial conducted on their product Epidiolex was deemed successful.
In a statement released by the British company, Epidiolex was found to have “induced a statistically significant improvement in reducing seizures” in patients with severe epilepsy during clinical trials.
After the news broke earlier this week, the company which is publicly traded saw their stocks rise by 16% to a record high 811 pence on the London Stock Exchange.
The next step for GW Pharma will be to seek approval from the U.S. Food and Drug Administration, to become the first approved cannabis extract in the States. This application is expected to go through during the first half of 2017.
Related News
Popular Posts
-
Cannabis Can Help Fight Alcoholism
I grew up in an era when Nancy Reagan’s “Just Say No” campaign proliferated through the airwav…
-
Patients often substitute medical marijuana for opioid pain medications and other drugs
Medical marijuana patients tend to reduce their use of prescription opioid pain medications, accordi…
-
Cannabinoids used in Sequence with Chemotherapy are a more Effective Treatment for Cancer
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in k…
-
Cannabis Extracts Associated With Reduced ADHD Symptoms
The administration of whole-plant cannabis extracts is associated with improvements in cognition and…
-
Research
Cannabidiol reverses the mCPP-induced increase in marble-burying behavior
Cannabidiol (CBD), one of the main components of Cannabis sp., presents clinical and preclinical anx…
-
Research
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as…
New Forum Posts
- 01/01/70